Apotex Reports Q1 Results as Public Company

The company’s performance indicates a stable core business, with revenue excluding the impact of the volume-limited license product (VLLP) growing 2% year-over-year. CEO Jeff Watson pointed to disciplined execution across the business and productivity initiatives aimed at securing over $100 million in savings throughout fiscal 2027. Despite a reported net loss of $38 million—largely attributed to higher finance expenses and the cessation of high-margin VLLP contributions—the company maintained an adjusted EBITDA margin of 31%.

Financial stability was bolstered by the recent IPO, which enabled the company to reduce leverage and secure an investment-grade rating from Morningstar DBRS. CFO Brian McClelland noted that the company has successfully expanded its revolving credit facility to $1.2 billion and transitioned to an unsecured debt structure, providing the flexibility needed for future capital allocation and growth investments. Apotex continues to focus on its 'Journey of Health' strategy, recently expanding its footprint through the acquisition of the Cumberland Pharmaceuticals portfolio and first-to-market launches for products such as semaglutide in Canada.